Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies (PROSTEPIRM)

Lille Catholic University

Status

Completed

Conditions

Fluorocholine

Prostatic Neoplasm

Positron-Emission Tomography

Treatments

Device: mpMRI

Device: PET Scan ou TEP-TDM

Study type

Interventional

Funder types

Other

Identifiers

NCT02971995

OBS025

Details and patient eligibility

About

Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection).

The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .

Enrollment

31 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with suspicion of prostate cancer
Patients who performed prostate mpMRI and F-Choline 18 PET scan
Patient capable of receiving clear informations
Patient giving a written consent for their participation via a consent signed by both parents of the patient (or legal tutor)
Patient covered by a healthcare insurance

Exclusion criteria